Coherent Expression Chromosome Cluster Analysis Reveals Differential Regulatory Functions of Amino-Terminal and Distal Parathyroid Hormone-Related Protein Domains in Prostate Carcinoma

I. Tsigelny, D. W. Burton, Y. Sharikov, R. H. Hastings, and L. J. Deftos

1 Department of Chemistry and Biochemistry, University of California, San Diego, CA 92093-0654, USA
2 San Diego Supercomputer Center, University of California, San Diego, CA 92093-0505, USA
3 Department of Medicine, University of California, San Diego, CA 92161-0813, USA
4 Anesthesiology Service, VA San Diego Healthcare System, Department of Anesthesiology, University of California, San Diego, CA 92161-8770, USA
5 Medicine Service, VA San Diego Healthcare System, Department of Medicine, University of California, San Diego, CA 92161-9111, USA

Received 14 February 2005; revised 10 May 2005; accepted 16 May 2005

Parathyroid hormone-related protein (PTHrP) has a number of cancer-related actions. While best known for causing hypercalcemia of malignancy, it also has effects on cancer cell growth, apoptosis, and angiogenesis. Studying the actions of PTHrP in human cancer is complicated because there are three isoforms and many derived peptides. Several peptides are biologically active at known or presumed cell surface receptors; in addition, the PTHrP-derived molecules can exert effects at the cell nucleus. To address this complexity, we studied gene expression in a DU 145 prostate cancer cell line that was stably transfected with control vector, PTHrP 1-173 and PTHrP 33-173. With this model, regulatory effects of the amino-terminal portion of PTHrP would result only from transduction with the full-length molecule, while effects pertaining to distal sequences would be evident with either construct. Analysis of the expression profiles by microarrays demonstrated nonoverlapping groups of differentially expressed genes. Amino-terminal PTHrP affected groups of genes involved in apoptosis, prostaglandin and sex steroid metabolism, cell-matrix interactions, and cell differentiation, while PTHrP 33-173 caused substantial increases in MHC class I antigen expression. This work demonstrates the distinct biological actions of the amino-terminus compared to distal mid-molecule or carboxy-terminal sequences of PTHrP in prostate carcinoma cells and provides targets for further study of the malignant process.

INTRODUCTION

Parathyroid hormone-related protein (PTHrP) is best known as the factor responsible for humoral hypercalcemia of malignancy, but it exerts other important effects in cancers and cancer cells. Among them are regulations of cell growth, apoptosis, cytokine production, and angiogenesis [1, 2, 3, 4]. Given these properties, it is not sur-
38-94 promotes placental calcium transfer [10], PTHrP 67-86 inhibits growth of breast carcinoma cells [11] and sensitizes lung alveolar epithelial cells to apoptosis [12]. Peptides included in PTHrP 107-141 inhibit osteoclast function [13], and PTHrP 140-173 regulates metabolism of orthophosphate by articular chondrocytes and protects lung cancer cells from apoptosis [14]. Cell surface receptors that mediate the effects of non-amino-terminal peptides have been postulated but have yet to be identified. PTHrP possesses a nuclear localizing sequence and can enter the nucleus to exert effects through an intracellular or intracrine mechanism [15]. The intracrine actions of PTHrP are frequently growth, or apoptosis related [2, 16]. Thus, the effects of PTHrP in an individual tissue can be regulated by expression of PTH1R and receptors yet to be discovered, by the cellular processing apparatus, and by nuclear localization and intracrine pathways.

The goal of this study was to use microarray technology to identify genes regulated by PTHrP in a prostate carcinoma cell line. We compared gene expression profiles between cells transfected with control vector, PTHrP 1-173 and PTHrP 33-173. This strategy provided a means to distinguish between the effects of amino-terminal PTHrP and the rest of the molecule. For example, a gene that was upregulated only by PTHrP 1-32 would be upregulated by PTHrP 1-173 and not by PTHrP 33-173, while one that was under the control of a region within PTHrP 33-173 would be upregulated by both constructs.

**MATERIALS AND METHODS**

**Cell culture**

The DU 145 human prostate cancer cell line [17] was obtained from American Type Culture Collection (Manassas, Va) and was grown in monolayer in RPMI 1640 media (Mediatech Inc, Herndon, Va) supplemented with 5% fetal bovine serum (Gemini Bio-Products, Woodland, Calif) at 37 °C in a humidified incubator with 95% air, 5% CO2. This cell line was selected because it has low constitutive PTHrP expression.

**Stable transfection**

PreproPTHrP 1-173 and preproPTHrP 33-173 constructs were directionally subcloned in the pCI-neo mammalian expression vector that utilizes the cytomegalovirus promoter for robust expression of the transgene (Promega Corp, Madison, Wis). The fidelities of the plasmids were confirmed by DNA sequencing and site-specific PTHrP immunooassays of cells transduced with the constructs [18]. The pCI-neo vector contains a neomycin resistance cassette that allows G418 selection of stable clones of DU 145 cells that express preproPTHrP 1-173 and preproPTHrP 33-173. The prepro-forms were used to facilitate PTHrP secretion [19].

**Microarray analysis**

The prostate cancer cells were seeded at a confluency of 75% in 100 mm tissue culture dishes at 37 °C in a humidified incubator with an atmosphere of 5% CO2. The next day, the media were aspirated from the dishes, the cells were washed with PBS, and serum-free medium was added to the cells for 18 h. The RNA was harvested by the RNase Q试剂 (Qiagen, Valencia, Calif) protocol, as per manufacturer’s recommendations. cDNAs were synthesized from the total RNA using a reverse transcriptase enzyme and biotin-labeled cRNAs were made using an RNA transcript labeling kit. The biotin-labeled RNA fragments were next hybridized to the probe array of a U133A Affymetrix GeneChip (Santa Clara, Calif), which contains 19,571 probe sets corresponding to approximately 16,000 separate genes. The hybridized array was stained with a streptavidin phycoerythrin conjugate and scanned by a GeneChip Scanner. The amount of light emitted at 570 nm was proportional to the bound target at each location on the probe array.

Six experiments were performed: two with the cells transfected only with the pCI-neo control vector, two with the cells transfected by preproPTHrP 1-173, and two with cells transfected by preproPTHrP 33-173.

**Bioinformatic analysis**

Initial signal preprocessing was performed as recommended by Affymetrix. We used the Affymetrix software normalization tools to enable the comparison of results from different chips. We restricted the analyses to the data for those genes in which two members of the experimental group (vector, PTHrP 1-173, PTHrP 33-173) each had “P” (present) detection levels. Gene expression values for the cells transfected by PTHrP were normalized to the average expression levels in the profiles for the cells transfected with control vector. To provide a biological framework for the observed changes in gene expression, we analyzed the genes that were up- or downregulated by PTHrP in terms of their biological process, molecular function, cell compartment, and signaling pathway, utilizing the terms established by the Gene Ontology (GO) Consortium [20]. We considered a significant change in gene expression after PTHrP transfection to be an increase of more than twofold or a decrease of more than 40% compared to cells transfected with vector control. We also included genes that were upregulated by a factor of >1.75-fold if they were closely clustered in one chromosomal location and shared gene ontology terms with other upregulated genes in that locus. A lower threshold was accepted in these cases because the location and ontology data represented additional information supporting a differential effect of PTHrP on gene expression.

**Criteria used to define coherent expression chromosome clusters**

Gene Ontology uses the following classes to group genes: molecular function (MF), cell compartment (CC),
biological process (BP), and signaling pathway (PW). We consider the cluster of genes on any chromosome as a “coherent expression chromosome cluster (CECC)” when a cluster of genes in a chromosome express together in a common pattern that is consistent with the following rules:

1. all genes of this region are over- or underexpressed due to exposure to a common factor (in our case PTHrP);
2. the genes are located in the same chromosomal banding region (or in the neighboring localization in two adjacent chromosome band regions);
3. the genes flanking the CECC have similar ontological definition(s) (MF or CC).

All of the genes that are regulated by PTHrP and lie between the two flanking genes having similar GO definitions are considered members of the CECC.

Examples of such analysis appear below.

(a) CECC on chromosome 6 (Figure 2). The CECC is located on the boundary of the bands 6.22 and 6.23 and

\[
\begin{align*}
\text{Ring protein (Zn-binding)} & \quad \text{CC}_1 \quad \text{MF}_1 \\
\text{DDR1} & \quad \text{CC}_2 \\
\text{HLA-B} & \quad \text{CC}_2 \quad \text{MF}_2 \quad \text{BP}_2 \\
\text{HLA-C} & \quad \text{CC}_2 \quad \text{MF}_2 \quad \text{BP}_2 \\
\text{HLA-A} & \quad \text{CC}_2 \quad \text{MF}_2 \quad \text{BP}_2 \\
\text{HLA-G} & \quad \text{CC}_2 \quad \text{MF}_2 \quad \text{BP}_2 \\
\text{HLA-F} & \quad \text{CC}_2 \quad \text{MF}_2 \quad \text{BP}_2 \\
\text{ZNF305 (Zn-binding)} & \quad \text{CC}_4 \quad \text{MF}_1 \\
\text{Butyrophilin CC2} & \quad \text{CC}_4
\end{align*}
\]

where \(\text{CC}_1\)—nuclear localization, \(\text{CC}_2\)—plasma membrane localization, \(\text{MF}_1\)—Zn binding, \(\text{MF}_2\)—MHC class I receptors, \(\text{BP}_2\)—immune response.

Here two separate CECCs appear to overlap each other flanked by Ring protein and ZNF305 in one case and by DDR1 and butyrophilin in the other. For the simplicity of explanation, we have considered it as a single CECC.

(b) CECC1 on chromosome 16 (Figure 3).

\[
\begin{align*}
\text{SF3B3 splicing factor} & \quad \text{CC}_1 \quad \text{MF}_1 \\
\text{Cytochrome B5} & \quad \text{CC}_2 \\
\text{cadherin 1-E} & \quad \text{CC}_3 \quad \text{MF}_3 \quad \text{BP}_3 \\
\text{cadherin 1-P} & \quad \text{CC}_3 \quad \text{MF}_3 \quad \text{BP}_3 \\
\text{FLJ} & \quad \text{CC}_1 \quad \text{MF}_1 \\
\text{PARD6A} & \quad \text{CC}_2 \\
\text{NOL3 nucleolar protein} & \quad \text{CC}_1
\end{align*}
\]

where \(\text{CC}_1\)—nuclear localization, \(\text{CC}_2\)—membrane localization, \(\text{CC}_3\)—integral to membrane, \(\text{MF}_1\)—DNA binding, \(\text{MF}_3\)—cell adhesion, calcium ion binding, \(\text{BP}_1\)—cell adhesion.

A group of genes within the CECC are not related by ontology to the flanking genes, but per definition are considered members of the CECC. They most probably are “switched on” by the same transcription activation factor as the rest of CECC.

RESULTS

Transfection of DU 145 cells with PTHrP 1-173 and PTHrP 33-173 expression plasmids increased the concentration of immunoreactive PTHrP that the cells released into the media by two- to fivefold compared to the amount secreted by cells transfected with vector. In prostate cancer cells, 17 genes were upregulated twofold or more by transfection with PTHrP 1-173 compared to vector control but the same genes were unaffected by the PTHrP 33-173 construct (Table 1). The most striking change involved three members of the aldo-keto reductase family, C1, C2, and C3, which were increased from 8- to 13-fold. This finding is notable because only 9 of the genes probed by the U133A chip, approximately 0.04% of the total, code for proteins with aldo-keto reductase activity, yet 19% of the genes that had GO terms and were upregulated by PTHrP 1-173 fell into that category. The aldo-keto reductase genes are all located on chromosome 10p15 (Figure 1). The PTHrP 1-173-upregulated group also included four genes involved in cell adhesion or cytoskeletal organization: cysteine-rich with EGF-like domains 1 (CRELD1), syndecan 2, nebulette, and junction plakoglobin. Finally, four genes out of the collection of 17 have been implicated in growth and/or apoptosis regulation, transforming growth factor \(\beta\) 2 (TGFB2), interferon induced protein 16 (IFI16), caspase 10 (CASP10), and p8 protein (candidate of metastasis) (P8).

The full-length PTHrP molecule downregulated 22 genes to less than 40% of control levels. These genes were not affected by the construct lacking the amino-terminal portion of PTHrP. The group was notable for a large number of genes involved in development or differentiation: pre-B-cell leukemia transcription factor 1 (PBX1), kinesin family member 5C (KIF5C), somatostatin (SST), diphtheria toxin receptor (DTR), gap junction protein alpha 1 (GJA1), connective tissue growth factor (CTGF), adipose differentiation-related protein (ADFP), myotubularin-related protein 2 (MTMR2), high mobility group AT-hook 2, and MAGEA8. PBX1 and HMGA2 mediate transcription factor-promoter interactions, and PBX1 and SST have interactions with Hox proteins. Several downregulated genes, including tumor necrosis factor receptor superfamily 25 (TNFRSF25), SST, diphtheria toxin receptor DTR, intestinal cell kinase (ICK), GJA1, ADFP, MTMR2, and interleukin 23 (IL23A) are involved in signal transduction.
Figure 1. Cluster of functionally similar genes induced by PTHrP 1-32 on chromosome 10. RNA from DU 145 prostate carcinoma cells that were stably transfected with PTHrP 1-173 (in gray), PTHrP 33-173 (in black), or vector was probed with an Affymetrix U133A array and analyzed for differential changes in gene expression between vector and PTHrP-transfected cells. The graph demonstrates a coherent expression cluster, a chromosomal region containing functionally related coregulated genes. The ordinate shows mRNA levels from the PTHrP-transfected cells expressed as a % of the levels measured in the vector-transfected cells. In this example from chromosome 10p15, the genes are members of the aldo-keto reductase family that are involved in the metabolism of prostaglandin D2 to prostaglandin F2α and in conversion of androgens to inactive forms. PTHrP 1-173 transfection caused an (8–13)-fold increase in levels for the three genes.

Figure 2. Functionally coherent expression induced by PTHrP 33-173. This graph represents data for chromosome 6p21-22 from the same experiment described in Figure 1. HLA-A, HLA-B, HLA-C, HLA-F, and HLA-F are all upregulated by PTHrP 33-173 in black (gray PTHrP 1-173). Ring finger protein 1 and two proteasome beta subunits, which are also upregulated, may work with the HLA antigens in a common pathway, since the proteasome is responsible for processing intracellular proteins to be presented on the cell surface with the HLA antigens.

The number of genes regulated by the non-amino-terminal portion of PTHrP was much larger than the number affected by amino-terminal PTHrP. PTHrP 33-173 upregulated 253 genes in DU 145 cells to levels > 200% of control cells and downregulated 103 genes. Table 2 presents a sampling of genes identified and organized by function. Several human leukocyte antigen (HLA) class I molecules, all located in close proximity on chromosome 6p21 (Figure 2), were upregulated by PTHrP 33-173 twofold or more. Interestingly, the 6p21-22 region also
Table 1. Genes regulated by PTHrP 1-173 but unaffected by PTHrP 33-173.

| Gene                                           | Unigene no | Region | Expression with PTHrP 1-173 transfection* (%) |
|------------------------------------------------|------------|--------|-----------------------------------------------|
| **Upregulated to >200% of control**           |            |        |                                               |
| Transforming growth factor, beta 2             | Hs.169 300 | 1q41   | 265                                           |
| Interferon, gamma-inducible protein 16         | 370 873    | 1q23   | 264                                           |
| ALL1-fused gene from chromosome 1q            | 75 823     | 1q21   | 271                                           |
| Interferon-induced protein 44                  | 82 316     | 1p31   | 344                                           |
| Caspase 10, apoptosis-related cysteine protease | 53 53      | 2q33   | 255                                           |
| Zinc finger protein 288                       | 436 987    | 3q13   | 281                                           |
| Cysteine-rich with EGF-like domains 1          | 93 83      | 3p25   | 253                                           |
| I factor (complement)                          | 312 485    | 4q25   | 494                                           |
| Rab coupling protein                           | 96 125     | 8p11   | 292                                           |
| Syndecan 2                                     | 150 1      | 8q22   | 253                                           |
| Aldo-keto reductase family 1, member C1        | 306 098    | 10p15  | 991                                           |
| Aldo-keto reductase family 1, member C2        | 201 967    | 10p15  | 1328                                          |
| Aldo-keto reductase family 1, member C3        | 78 183     | 10p15  | 785                                           |
| Hypothetical protein FLJ12616                  | 287 537    | 10q26  | 260                                           |
| Nebulette                                      | 50 25      | 10p12  | 277                                           |
| p8 protein (candidate of metastasis 1)         | 418 692    | 16p11  | 263                                           |
| Junction plakoglobin                           | 23 40      | 17q21  | 298                                           |
| **Downregulated to <40% of control**          |            |        |                                               |
| Tumor necrosis factor receptor superfamily, member 24 | 299 558  | 1p36   | 20                                            |
| Pre-B-cell leukemia transcription factor 1     | 40 822     | 1q23   | 23                                            |
| Kinesin family member 5C                      | 66 41      | 2q23   | 39                                            |
| Butyrylcholinesterase                         | 422 857    | 3q26   | 21                                            |
| Somatostatin                                   | 12 409     | 3q28   | 31                                            |
| Hypothetical protein FLJ23235                  | 211 501    | 4p14   | 34                                            |
| Hypothetical protein FLJ23548                  | 22 895     | 4q26   | 39                                            |
| Hypothetical protein DKFZp434N1235             | 149 030    | 4q28   | 12                                            |
| Potassium intermediate/small conductance       |            |        |                                               |
| Calcium-activated channel, subfamily N, member 2 | 98 280  | 5q22   | 16                                            |
| Lysyl oxidase                                  | 102 267    | 5q23   | 32                                            |
| Diphtheria toxin receptor                      | 799        | 5q23   | 36                                            |
| Intestinal cell kinase                         | 417 022    | 6p12   | 37                                            |
| Connexin 43                                    | 74 471     | 6q21   | 29                                            |
| Connective tissue growth factor                | 410 037    | 6q23   | 33                                            |
| Adipose differentiation-related protein         | 34 16      | 9p22   | 34                                            |
| Myotubularin-related protein 2                 | 181 326    | 11q22  | 38                                            |
| Interleukin 23, alpha subunit p19              | 98 309     | 12q13  | 33                                            |
| High mobility group AT-hook 1                  | 57 301     | 6p21   | 36                                            |
| Heat shock 105kD                                | 36 927     | 13q12  | 36                                            |
| Glycine amidinotransferase                     | 75 335     | 15q15  | 39                                            |
| Ubiquitin-like 5                               | 386 532    | 19p13  | 16                                            |
| Melanoma antigen, family A, 8                  | 37 109     | Xq28   | 39                                            |

*Expression is presented as a % of the expression by the vector-transfected control cells.

This includes three upregulated genes coding for a ring finger protein (RING1) and two components of the proteasome, beta subunits 8 and 9 (PSMB8,PSMB9). These proteins are functionally related to the major histocompatibility complex proteins because the proteasome processes peptides for presentation with HLA I proteins [21]. Furthermore, RING1 is involved in monoubiquitination of proteins targeted for proteasomal processing [22]. Thus,
6p21-22 contains an amplicon of genes with related functional properties that share responsiveness to PTHrP 33-173, a feature we term a coherent expression cluster. Chromosome 16 (Figure 3) also contains a coherent expression cluster for PTHrP 33-173 consisting of a pair of genes. E-cadherin (CDH1) and P-cadherin (CDH3), which are both involved in cell–cell interaction [23, 24, 25], lie within a 0.15 megabase region on chromosome 16p22. PTHrP 33-173 downregulated several genes coding for proteins involved in cell-matrix or cytoskeletal interaction and also decreased expression of DICRI, a Dcr-1 homolog. DICER1 codes for a ribonuclease that produces active small RNA components involved in repressing gene expression [26].

PTHrP regulated a total of 245 annotated genes in DU 145 cells. Of this group, 219 were found in CECCs and 26 were not. Other investigators have estimated that 20% of the expressed annotated genes on the Affymetrix U133A chip may fall into functional clusters [27]. Thus, the number of PTHrP-regulated genes included in CECCs was much greater than expected on the basis of chance alone (Chi square P < .0001).

DISCUSSION

This work utilized a novel approach to microarray analysis to demonstrate distinct pathway- or process-specific differences in the pattern of gene expression induced by amino-terminal versus distal sequences of PTHrP. We compared microarray data from human prostate carcinoma cells transfected with full-length PTHrP 1-173 versus cells expressing a non-amino-terminal peptide, PTHrP 33-173, which lacks the amino-terminal sequence. We have attempted to generate smaller PTHrP peptides on the order of PTHrP 1-32 with transfected expression plasmids. However, transfection with these plasmids does not appear to generate immunoreactive PTHrP, presumably because the molecules are too short to transverse the endoplasmic reticulum [19]. With the comparison between PTHrP 1-173 and PTHrP 33-173, a change in function that depended on amino-terminal PTHrP would be observed only after transduction with PTHrP 1-173, while effects due to distal PTHrP sequences, common to both PTHrP forms, would be apparent with either construct. Amino-terminal PTHrP comprises PTHrP 1-32, a physiologic ligand for the receptor shared with the amino-terminus of PTH. The distal region contains mid-molecule and carboxy-terminal sequences that also exert biologic activity, but have no known receptors [28]. The mid-molecule region also contains a nuclear localizing sequence (NLS) at residues 87–106 and an adjacent sequence at amino acids 107–139 that are important for intracrine effects [15, 29]. The sequence of PTHrP 65–171 is 39% homologous to CHD-4, a nuclear DNA binding protein. Structural studies are ongoing to evaluate whether a DNA binding function with this region is important for PTHrP intracrine effects. Thus, PTHrP could influence prostate cancer pathology through multiple mechanisms; these mechanisms could be modulated by protein processing, changes in secretory pattern, receptor expression, and nuclear localization.

We found that regulation of genes in several pathways and biologic processes varied in a manner dependent on specific PTHrP regions. Amino-terminal PTHrP increased mRNA levels for several aldo-keto reductase (AKR) enzymes (Table 1), genes related to cell adhesion and cytoskeleton, and genes regulating growth and/or apoptosis, effects not observed with cells transfected with the cut version of PTHrP. In addition, the amino-terminal
Table 2. Representative genes regulated by PTHrP 33-173.

| Gene                                      | Unigene no | Expression with PTHrP 33-173 transfection* (%) |
|-------------------------------------------|------------|-----------------------------------------------|
| **Upregulated genes**                     |            |                                               |
| **Class 1 major histocompatibility complex proteins** |            |                                               |
| HLA-A                                     | Hs. 181 244 | 6p21                                          | 224                                           |
| HLA-B                                     | Hs. 77 961  | 6p21                                          | 200                                           |
| HLA-C                                     | Hs. 274 485 | 6p21                                          | 201                                           |
| HLA-F                                     | Hs. 411 958 | 6p21                                          | 180                                           |
| HLA-G                                     | Hs. 512 152 | 6p21                                          | 242                                           |
| **Proteasome-related proteins**           |            |                                               |
| Proteasome (prosome, macropain) subunit, beta type, 8 | Hs. 180 062 | 6p21                                          | 358                                           |
| Proteasome (prosome, macropain) subunit, beta type, 9 | Hs. 381 081 | 6p21                                          | 318                                           |
| Ring finger protein 1, RING1              | Hs. 202 430 | 6p21                                          | 249                                           |
| **Proteins mediating cell-cell interactions** |          |                                               |
| E-cadherin, CDH1                          | Hs. 194 657 | 16q22                                         | 334                                           |
| P-cadherin, CDH3                          | Hs. 191 842 | 16q22                                         | 229                                           |
| **Arachidonic acid pathway proteins**     |            |                                               |
| Glutathione peroxidase 1, GPX1            | Hs. 76 686  | 3p21                                          | 200                                           |
| Glutathione peroxidase 3, GPX3            | Hs. 386 793 | 5q23                                          | 718                                           |
| **Nuclear proteins**                      |            |                                               |
| Basic leucine nuclear zipper factor Jem-1, BLZF1 | Hs. 444 697 | 1q24                                          | 221                                           |
| Kruppel-like factor 3, KLF3               | Hs. 145 754 | 4p14                                          | 197                                           |
| Zinc finger protein 305, ZNF305           | Hs. 134 816 | 6p22                                          | 229                                           |
| **Downregulated genes**                   |            |                                               |
| **Cell-Matrix/Cytoskeleton-related proteins** |          |                                               |
| Sterile alpha motif domain containing 4, SAMD4 | Hs. 98 259  | 14q22                                         | 22                                            |
| Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 4 | Hs. 439 530  | 12p13                                         | 33                                            |
| Myosin light polypeptide kinase, MYLK      | Hs. 386 078 | 3q21                                          | 10                                            |
| Transmembrane 4 superfamily member 2, TM4SF2 | Hs. 439 586  | Xp11                                          | 34                                            |
| Lysyl oxidase-like 2, LOXL2               | Hs. 83 354  | 8p21                                          | 37                                            |
| Dicer1, Dcr-1 homolog, DICER1             | Hs. 87 889  | 14q32                                         | 34                                            |

*Expression is presented as a % of the expression by vector-transfected control cells.

region decreased expression of genes with a role in differentiation or development. In contrast, the effects of the distal 33–173 residue portion of the molecule were notable in regard to expression of genes for MHC I proteins, proteasome function, cell-cell interaction, arachidonic acid metabolism, nuclear proteins, and cell-matrix and cytoskeleton-related proteins (Table 2). Multiple genes from the same pathway were frequently regulated in a coordinated fashion. The HLA genes and proteasomal subunit genes PSMB8 and PSMN9 represent such a set, since the proteasome prepares short peptides for antigen presentation on MHC-1. Similarly, GLG1, the TGF-beta complex protein, and cadherins all participate in the TGF-beta pathway. In some cases, amino-terminal PTHrP and distal PTHrP appeared to act on related functional pathways. The effects of the amino-terminal and carboxy-terminal domains on AKR enzymes and on proteins with a role in arachidonic acid pathways exemplify this situation. The enzymes upregulated by PTHrP 1-173 are involved in prostaglandin metabolism [30], while in the PTHrP 33-173-regulated group, glutathione peroxidases 1 and 3 inhibit 12-lipoxygenase and, to a lesser degree 5-lipoxygenase [31, 32]. In addition, amino-terminal PTHrP and distal PTHrP both have effects on several cell-matrix and cytoskeleton genes, although the proximal sequences upregulate expression and the distal sequences decrease expression.

Exogenous PTHrP peptides do have biologic actions in wild-type DU 145 cells. For example, we have evaluated their effects on staurosporine-induced apoptosis. PTHrP140-173 peptide treatment decreased caspases-3 and -9 activities and nuclear condensation compared to vehicle treated cells. No significant effects on nuclear condensation and caspases-3 or -9 were observed with treatment with PTHrP 1-34 or scrambled PTHrP 140-173 peptide [32]. Since protective effects on apoptosis
were not observed for PTHrP 1-34, the human-specific 140-173 region appears responsible for the antiapoptotic properties of PTHrP in prostate cancer cells through a paracrine mechanism. These results would be consistent with effects mediated by transfection with either the PTHrP 1-173 or the PTHrP 33-173 construct.

The genes affected by PTHrP 1-173 and PTHrP 33-173 could have variable effects on prostate carcinoma progression or metastasis. In several instances, both PTHrP forms had actions that could retard cancer growth. For example, the apoptosis genes upregulated by PTHrP 1-173 only were generally proapoptotic and could conceivably promote prostate cancer cell death. There are a number of precedents for apoptosis sensitization by amino-terminal PTHrP. PTHrP 1-32 induces or augments apoptosis in human embryonic kidney (HEK) 293 cells [33], postconfluent mesenchymal cells [34], and lung alveolar type II cells [12]. Just as apoptosis enhancement would slow tumor growth, the effects of carboxy-terminal PTHrP on HLA class I expression and proteasomal function could hinder carcinoma progression. Many prostate cancer cells and other cancer cells downregulate MHC antigens, presumably as a mechanism of avoiding immune surveillance [35, 36]. HLA class I antigen expression decreases in more invasive prostate carcinomas and expression is directly related to patient survival [37]. By upregulating these molecules, PTHrP 33-173 expression could improve the ability of CDBT cells to detect and kill prostate tumor cells [36]. Finally, increased expression of the glutathione peroxidase enzymes mediated by distal PTHrP sequences could negatively influence prostate tumor growth. By inhibiting 5- and 12-lipoxygenase, GPX1 would reduce cancer cell levels of 5-HETE and 12-HETE, mediators that promote survival, growth, and invasiveness of prostate cancer cells [38, 39, 40]. On the other hand, increased expression of the AKR enzymes could augment prostate cancer growth. AKR1C13 could limit production of PPARγ ligands arising from PGJ2 by favoring PGF2α, rather than PGJ2, production from PGD2. Decreasing these ligands could support tumor progression because PPARγ has antiproliferative effects in prostate cancer cells and promotes cell death [41, 42]. It should be noted that upregulation of the AKR enzymes could also be significant in prostate cancer in terms of effects on androgen levels. The AKR1C isoforms are involved in inactivating male and female sex hormones [43]. For example, they catalyze the conversion of 5α-dihydrotestosterone to 5α-androstan-3α, 17β-diol, a much less potent androgen [44], thereby regulating occupancy and activation of the androgen receptor. Increased expression of E-cadherin and P-cadherin would also favor prostate carcinoma growth. E-cadherin has a positive relationship with tumor invasiveness. Thus, the differentially expressed genes regulated by PTHrP may either stimulate or retard cancer progression. The overall effect of amino- and non-amino-terminal PTHrP on the pathophysiology of prostate cancer will require direct experimental evaluation.

The changes in gene expression induced by PTHrP were notable for including several coherent expression clusters, including the AKR enzymes on chromosome 10p15, the HLA class I antigens and proteasomal pathway proteins on chromosome 6p21 and the E-cadherin/P-cadherin pair on chromosome 16q22. These findings are not unusual because genes with similar functions tend to occur in adjacent positions along chromosomes. For example, the individual members of pairs of adjacent yeast genes shared the same functional category in 387 of 2018 pairs (19%), significantly more than would be expected by chance [45]. Clustering of genes with organ-specific function has been observed in humans, as well [46]. Chromosomal clustering of differentially expressed genes could result from either genomic changes or transcriptional mechanisms. In our experiments involving transduction with a single gene, widespread genomic changes are unlikely and transcriptional control is a more probable explanation for regionally coherent changes in expression patterns. This control could take the form of common responses to transcription factors among functionally similar genes. As an example, E-cadherin and P-cadherin have homology in their 5′-promoter regions, which are both recognized by Sp1-related nuclear factors [47]. Similarly, expression of HLA class I genes is mediated by conserved cis-acting regulatory elements, including the enhancer A, the ISRE module, and the SXY module [48]. Alternatively, coherent expression clusters could arise from epigenetic mechanisms involving changes in chromatin structure. Thus, histone deacetylase inhibitors have been shown to enhance expression of MHC class I antigens in tumor cells [49].

The observation that non-amino-terminal PTHrP caused differential expression of many more genes than amino-terminal PTHrP was somewhat unexpected. The result is understandable, however, given the multifunctional nature of PTHrP. Genes regulated solely by PTHrP 1-173 and not PTHrP 33-173 are under the control of paracrine interactions of PTHrP 1-32 with its receptor. In contrast, genes regulated by PTHrP 33-173 may be affected by paracrine interactions with any of the downstream biologically active portions of the PTHrP molecule, as well as intracrine mechanisms. Furthermore, the effect of PTHrP 33-173 transfection on expression of Dicer1 could be an additional explanation for the augmented number of differentially expressed genes. Dicer is an RNAse that produces RNAi activity. Depletion of Dicer reduces such activity in drosophila cells, while C elegans lacking functional Dicer are impaired in RNAi-mediated gene suppression [50, 51]. Thus, a reduction in Dicer expression after PTHrP 33-173 transduction in prostate cancer cells could contribute to a general increase in gene expression by reducing RNAi activity.

Our studies introduce a novel method to identify effects of PTHrP that are specific to functional peptide domains contained within this polypeptide. Our results show that PTHrP can exert nonoverlapping biological effects in prostate carcinoma cells that are attributable...
to amino-terminal and non-amino-terminal domains. Amino-terminal PTHrP regulated groups of genes involved in growth/apoptosis, prostaglandin and androgen steroid metabolism, cell-matrix interactions, and development/differentiation. Large changes were seen in aldo-keto reductase genes that could play a role androgen response. On the other hand, PTHrP 33-173 effects were significant for increases in expression of HLA class I antigens and the proteasomal proteins that could be involved in antigen presentation. These changes could render prostate carcinoma cells more susceptible to immune surveillance and might constitute a rationale for a PTHrP-based therapy for prostate cancer. Finally, our work has identified coherent expression clusters, chromosomal regions of increased differential gene expression after PTHrP transduction. Two interesting clusters involved the aldo-keto reductase genes on chromosome 10p15 and the HLA genes on chromosome 6p21. Comparing microarray analysis results from cells transduced with different forms of a regulatory protein provides a mechanism for elucidating domain-specific effects in gene expression. Further application of this novel approach to microarray analysis with other PTHrP species can help to elucidate the complex effects that PTHrP exerts on cancer cells.

ACKNOWLEDGMENTS

This work was supported by VA Merit Review Grants (Hastings and Deftos), NIH Grants ES09227 (Hastings) and DK60588 (Deftos), and the California Tobacco-Related Disease Research Program Grant no 10RT-0161. We thank Dr. Garret Hampton, Genomics Institute of Novartis Research Foundation, La Jolla, Calif, for generously providing parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res. 1999;59(23):6015–6022.

REFERENCES

[1] Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept. 2002;105(2):109–120.
[2] Tovar Sepulveda VA, Shen X, Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology. 2002;143(2):596–606.
[3] Bakre MM, Zhu Y, Yin H, et al. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med. 2002;8(9):995–1003.
[4] Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kB activation in osteoblastic cells. J Biol Chem. 2002;277(31):28109–28117.
[5] Dougherty KM, Blomme EA, Koh AJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res. 1999;59(23):6015–6022.
[6] Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer. 1999;80(2):257–264.
[7] Rabbani SA, Gladu J, Liu B, Goltzman D. Regulation in vivo of the growth of Leydig cell tumors by antisense ribonucleic acid for parathyroid hormone-related peptide. Endocrinology. 1995;136(12):5416–5422.
[8] Takai E, Yano T, Iguchi H, et al. Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma. Cancer. 1996;78(7):1384–1387.
[9] Abou-Samra AB, Juppner H, Force T, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA. 1992;89(7):2732–2736.
[10] Care AD, Abbas SK, Pickard DW, et al. Stimulation of ovine placental transport of calcium and magnesium by mid-molecule fragments of human parathyroid hormone-related protein. Exp Physiol. 1990;75(4):605–608.
[11] Luparello C, Romanotto R, Tipa A, et al. Mid-regions of parathyroid hormone-related protein inhibits growth and invasion in vitro and tumorigenesis in vivo of human breast cancer cells. J Bone Miner Res. 2001;16(12):2173–2181.
[12] Hastings RH, Quintana RA, Sandoval R, et al. Proapoptotic effects of parathyroid hormone-related protein in type II pneumocytes. Am J Respir Cell Mol Biol. 2003;29(6):733–742.
[13] Zheng MH, McCaughan HB, Papadimitriou JM, Nicholson GC, Wood DJ. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein. J Cell Biochem. 1994;54(2):145–153.
[14] Hastings RH, Araiza F, Burton DW, Zhang L, Bedley M, Deftos LJ. Parathyroid hormone-related protein ameliorates death receptor-mediated apoptosis in lung cancer cells. Am J Physiol Cell Physiol. 2003;285(6):C1429–C1436.
[15] Henderson JE, Amizuka N, Warshawsky H, et al. Nucleolar localization of parathyroid hormone-related...
peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. *Mol Cell Biol.* 1995;15(8):4064–4075.

[16] Ye Y, Falzon M, Seitz PK, Cooper CW. Overexpression of parathyroid hormone-related protein promotes cell growth in the rat intestinal cell line IEC-6. *Regul Pept.* 2001;99(2-3):169–174.

[17] Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). *Int J Cancer.* 1978;21(3):274–281.

[18] Hastings RH, Quintana RA, Sandoval R, Burton DW, Deftos LJ. Amino-terminal and mid-molecule parathyroid hormone-related protein, phosphatidylycholine, and type II cell proliferation in silica-injured lung. *Am J Physiol Lung Cell Mol Physiol.* 2003;285(6):L1312–L1322.

[19] Ditmer LS, Burton DW, Deftos LJ. Elimination of the carboxy-terminal sequences of parathyroid hormone-related protein 1-173 increases production and secretion of the truncated forms. *Endocrinology.* 1996;137(5):1608–1617.

[20] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet.* 2000;25(1):25–29.

[21] Shastri N, Schwab S, Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. *Annu Rev Immunol.* 2002;20:463–493.

[22] Hwang WW, Venkatasubrahmanyam S, Ianculescu AG, Tong A, Boone C, Madhani HD. A conserved RING finger protein required for histone H2B monoubiquitination and cell size control. *Mol Cell.* 2003;11(1):261–266.

[23] Oesterreich S, Deng W, Jiang S, et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. *Cancer Res.* 2003;63(17):5203–5208.

[24] Riethmacher D, Brinkmann V, Birchmeier C. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. *Proc Natl Acad Sci USA.* 1995;92(3):855–859.

[25] Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. *Cancer Cell Int.* 2003;3(1):17.

[26] Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. *Curr Opin Cell Biol.* 2004;16(3):223–229.

[27] Reyal F, Stransky N, Bernard-Pierrot I, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes—a study of 130 invasive ductal breast carcinomas. *Cancer Res.* 2005;65(4):1376–1383.

[28] Orloff JJ, Reddy D, de Papp AE, Yang KH, Soifer NE, Stewart AF. Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. *Endocr Rev.* 1994;15(1):40–60.

[29] de Miguel F, Fiaschi-Taesch N, Lopez-Talavera JC, et al. The C-terminal region of PTHrP, in addition to the nuclear localization signal, is essential for the intracellular stimulation of proliferation in vascular smooth muscle cells. *Endocrinology.* 2001;142(9):4096–4105.

[30] Matsuura K, Shiraishi H, Hara A, et al. Identification of a principal miRNA species for human 3alpha-hydroxysteroid dehydrogenase isofrom (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. *J Biochem (Tokyo).* 1998;124(5):940–946.

[31] Chen CJ, Huang HS, Chang WC. Depletion of phospholipid hydroperoxide glutathione peroxidase up-regulates arachidonic metabolism by 12S-lipoxygenase and cyclooxygenase 1 in human epidermoid carcinoma A431 cells. *FASEB J.* 2003;17(12):1694–1696.

[32] Maheshvari VV, Burton DW, Hastings RH, Aguilera JA, Pardo FS, Deftos LJ. Apoptotic effects of parathyroid hormone related protein in prostate cancer cells. *J Bone Miner Res.* 2003;18:S119.

[33] Turner PR, Mefford S, Christakos S, Nissenson RA. Apoptosis mediated by activation of the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein (PTHrP). *Mol Endocrinol.* 2000;14(2):241–254.

[34] Chen HL, Demiralp B, Schneider A, et al. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. *J Biol Chem.* 2002;277(22):19374–19381.

[35] Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. *Urology.* 1995;46:681–686.

[36] Cresswell P. Cell biology. Cutting and pasting antigenic peptides. *Science.* 2004;304(5670):525–527.

[37] Levin I, Klein T, Kuperman O, et al. The expression of HLA class I antigen in prostate cancer in relation to tumor differentiation and patient survival. *Cancer Detect Prev.* 1994;18(6):443–445.

[38] Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. *Cancer Metastasis Rev.* 2001;20(3-4):195–206.

[39] Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. *J Natl Cancer Inst.* 1994;86(15):1145–1151.

[40] Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. *Cancer Res.* 2002;62(9):2721–2727.

[41] Segawa Y, Yoshimura R, Hase T, et al. Expression of peroxisome proliferator-activated receptor (PPAR)
in human prostate cancer. *Prostate.* 2002;51(2):108–116.

[42] Butler R, Mitchell SH, Tindall DJ, Young CY. Non-apoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. *Cell Growth Differ.* 2000;11(1):49–61.

[43] Penning TM, Burczynski ME, Jez JM, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. *Biochem J.* 2000;351(pt 1):67–77.

[44] Rizner TL, Lin HK, Penning TM. Role of human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells. *Chem Biol Interact.* 2003;143-144:401–409.

[45] Cohen BA, Mitra RD, Hughes ID, Church GM. A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression. *Nat Genet.* 2000;26(2):183–186.

[46] Yamashita T, Honda M, Takatori H, Nishino R, Hoshino N, Kaneko S. Genome-wide transcriptome mapping analysis identifies organ-specific gene expression patterns along human chromosomes. *Genomics.* 2004;84(5):867–875.

[47] Faraldo ML, Rodrigo I, Behrens J, Birchmeier W, Cano A. Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. *Mol Carcinog.* 1997;20(1):33–47.

[48] van den Elsen PJ, Gobin SJ. The common regulatory pathway of MHC class I and class II transactivation. *Microbes Infect.* 1999;1(11):887–892.

[49] Magner WJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. *J Immunol.* 2000;165(12):7017–7024.

[50] Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature.* 2001;409(6818):363–366.

[51] Knight SW, Bass BL. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. *Science.* 2001;293(5538):2269–2271.